Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota,...
Gespeichert in:
| Veröffentlicht in: | Science Progress 2024-04, Vol.107 (2), p.368504241253709-368504241253709 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368504241253709 |
|---|---|
| container_issue | 2 |
| container_start_page | 368504241253709 |
| container_title | Science Progress |
| container_volume | 107 |
| creator | Bai, Junyi Wang, Ying Li, Fuhao Wu, Yueyao Chen, Jun Li, Meng Wang, Xi Lv, Bin |
| description | Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action. |
| doi_str_mv | 10.1177/00368504241253709 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11113063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_00368504241253709</sage_id><sourcerecordid>3059256386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-e99a15681ed434c23f4bdb4ec22b681973c4174528704ce9291ce73d757107c3</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMozvj4AW4k4MZNNc-mdSOD-AJBEJdCSNNbp0Pb1KQzg__eDONbzCaQ-51zczgIHVByQqlSp4TwNJNEMEGZ5IrkG2jMiFCJoinfROPVPFkBI7QTwowQKmmabaMRz5TKFJNj9PQAAYy3U2zKhekstNANAZuuxD340IMd6gUE7Cpcd1Vj2tYMzr_iwi2hwWUdxQHO8ARb1_YeptCFyGMPixqWe2irMk2A_fd7Fz1eXT5e3CR399e3F5O7xAqaDwnkuaEyzSiUggvLeCWKshBgGSvia6545JSQLFNEWMhZTi0oXiqpKFGW76LztW0_L1oobUzgTaN7X7fGv2pnav1z0tVT_ewWmsbDScqjw_G7g3cvcwiDbutgoWlMB24eNCcyZzLlWRrRo1_ozM19F-NFKuOKCpaSSNE1Zb0LwUP1-RtK9Ko7_ae7qDn8HuNT8VFWBE7WQDDP8LX2f8c3iRmhyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3083714260</pqid></control><display><type>article</type><title>Research advancements and perspectives of inflammatory bowel disease: A comprehensive review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Bai, Junyi ; Wang, Ying ; Li, Fuhao ; Wu, Yueyao ; Chen, Jun ; Li, Meng ; Wang, Xi ; Lv, Bin</creator><creatorcontrib>Bai, Junyi ; Wang, Ying ; Li, Fuhao ; Wu, Yueyao ; Chen, Jun ; Li, Meng ; Wang, Xi ; Lv, Bin</creatorcontrib><description>Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.</description><identifier>ISSN: 0036-8504</identifier><identifier>EISSN: 2047-7163</identifier><identifier>DOI: 10.1177/00368504241253709</identifier><identifier>PMID: 38778725</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Abnormalities ; Animals ; Biological Products - therapeutic use ; Corticoids ; Corticosteroids ; Crohn's disease ; Drug development ; Drugs ; Environmental factors ; Gastrointestinal Microbiome - drug effects ; Humans ; Immunology ; Immunomodulation ; Immunomodulators ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Inflammatory Bowel Diseases - drug therapy ; Intestinal microflora ; Intestine ; Medicine & Health Sciences ; MicroRNAs - genetics ; miRNA ; Nanoparticles ; Natural products ; Pathogenesis ; Pharmacology ; Reagents ; Remission ; RNA, Long Noncoding - genetics ; Salicylic acid ; Ulcerative colitis</subject><ispartof>Science Progress, 2024-04, Vol.107 (2), p.368504241253709-368504241253709</ispartof><rights>The Author(s) 2024</rights><rights>2024. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/ ) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page ( https://us.sagepub.com/en-us/nam/open-access-at-sage ). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c419t-e99a15681ed434c23f4bdb4ec22b681973c4174528704ce9291ce73d757107c3</cites><orcidid>0009-0004-1627-7933</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113063/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113063/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,725,778,782,790,862,883,21949,27836,27905,27907,27908,44928,45316,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38778725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Junyi</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Li, Fuhao</creatorcontrib><creatorcontrib>Wu, Yueyao</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><creatorcontrib>Li, Meng</creatorcontrib><creatorcontrib>Wang, Xi</creatorcontrib><creatorcontrib>Lv, Bin</creatorcontrib><title>Research advancements and perspectives of inflammatory bowel disease: A comprehensive review</title><title>Science Progress</title><addtitle>Sci Prog</addtitle><description>Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.</description><subject>Abnormalities</subject><subject>Animals</subject><subject>Biological Products - therapeutic use</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>Crohn's disease</subject><subject>Drug development</subject><subject>Drugs</subject><subject>Environmental factors</subject><subject>Gastrointestinal Microbiome - drug effects</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunomodulation</subject><subject>Immunomodulators</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Medicine & Health Sciences</subject><subject>MicroRNAs - genetics</subject><subject>miRNA</subject><subject>Nanoparticles</subject><subject>Natural products</subject><subject>Pathogenesis</subject><subject>Pharmacology</subject><subject>Reagents</subject><subject>Remission</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Salicylic acid</subject><subject>Ulcerative colitis</subject><issn>0036-8504</issn><issn>2047-7163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1kUtLxDAUhYMozvj4AW4k4MZNNc-mdSOD-AJBEJdCSNNbp0Pb1KQzg__eDONbzCaQ-51zczgIHVByQqlSp4TwNJNEMEGZ5IrkG2jMiFCJoinfROPVPFkBI7QTwowQKmmabaMRz5TKFJNj9PQAAYy3U2zKhekstNANAZuuxD340IMd6gUE7Cpcd1Vj2tYMzr_iwi2hwWUdxQHO8ARb1_YeptCFyGMPixqWe2irMk2A_fd7Fz1eXT5e3CR399e3F5O7xAqaDwnkuaEyzSiUggvLeCWKshBgGSvia6545JSQLFNEWMhZTi0oXiqpKFGW76LztW0_L1oobUzgTaN7X7fGv2pnav1z0tVT_ewWmsbDScqjw_G7g3cvcwiDbutgoWlMB24eNCcyZzLlWRrRo1_ozM19F-NFKuOKCpaSSNE1Zb0LwUP1-RtK9Ko7_ae7qDn8HuNT8VFWBE7WQDDP8LX2f8c3iRmhyQ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Bai, Junyi</creator><creator>Wang, Ying</creator><creator>Li, Fuhao</creator><creator>Wu, Yueyao</creator><creator>Chen, Jun</creator><creator>Li, Meng</creator><creator>Wang, Xi</creator><creator>Lv, Bin</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>F28</scope><scope>FR3</scope><scope>JQ2</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0004-1627-7933</orcidid></search><sort><creationdate>20240401</creationdate><title>Research advancements and perspectives of inflammatory bowel disease: A comprehensive review</title><author>Bai, Junyi ; Wang, Ying ; Li, Fuhao ; Wu, Yueyao ; Chen, Jun ; Li, Meng ; Wang, Xi ; Lv, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-e99a15681ed434c23f4bdb4ec22b681973c4174528704ce9291ce73d757107c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abnormalities</topic><topic>Animals</topic><topic>Biological Products - therapeutic use</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>Crohn's disease</topic><topic>Drug development</topic><topic>Drugs</topic><topic>Environmental factors</topic><topic>Gastrointestinal Microbiome - drug effects</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunomodulation</topic><topic>Immunomodulators</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Medicine & Health Sciences</topic><topic>MicroRNAs - genetics</topic><topic>miRNA</topic><topic>Nanoparticles</topic><topic>Natural products</topic><topic>Pathogenesis</topic><topic>Pharmacology</topic><topic>Reagents</topic><topic>Remission</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Salicylic acid</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Junyi</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Li, Fuhao</creatorcontrib><creatorcontrib>Wu, Yueyao</creatorcontrib><creatorcontrib>Chen, Jun</creatorcontrib><creatorcontrib>Li, Meng</creatorcontrib><creatorcontrib>Wang, Xi</creatorcontrib><creatorcontrib>Lv, Bin</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>ANTE: Abstracts in New Technology & Engineering</collection><collection>Engineering Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Science Progress</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Junyi</au><au>Wang, Ying</au><au>Li, Fuhao</au><au>Wu, Yueyao</au><au>Chen, Jun</au><au>Li, Meng</au><au>Wang, Xi</au><au>Lv, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Research advancements and perspectives of inflammatory bowel disease: A comprehensive review</atitle><jtitle>Science Progress</jtitle><addtitle>Sci Prog</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>107</volume><issue>2</issue><spage>368504241253709</spage><epage>368504241253709</epage><pages>368504241253709-368504241253709</pages><issn>0036-8504</issn><eissn>2047-7163</eissn><abstract>Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>38778725</pmid><doi>10.1177/00368504241253709</doi><orcidid>https://orcid.org/0009-0004-1627-7933</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-8504 |
| ispartof | Science Progress, 2024-04, Vol.107 (2), p.368504241253709-368504241253709 |
| issn | 0036-8504 2047-7163 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11113063 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Abnormalities Animals Biological Products - therapeutic use Corticoids Corticosteroids Crohn's disease Drug development Drugs Environmental factors Gastrointestinal Microbiome - drug effects Humans Immunology Immunomodulation Immunomodulators Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Intestinal microflora Intestine Medicine & Health Sciences MicroRNAs - genetics miRNA Nanoparticles Natural products Pathogenesis Pharmacology Reagents Remission RNA, Long Noncoding - genetics Salicylic acid Ulcerative colitis |
| title | Research advancements and perspectives of inflammatory bowel disease: A comprehensive review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T12%3A53%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Research%20advancements%20and%20perspectives%20of%20inflammatory%20bowel%20disease:%20A%20comprehensive%20review&rft.jtitle=Science%20Progress&rft.au=Bai,%20Junyi&rft.date=2024-04-01&rft.volume=107&rft.issue=2&rft.spage=368504241253709&rft.epage=368504241253709&rft.pages=368504241253709-368504241253709&rft.issn=0036-8504&rft.eissn=2047-7163&rft_id=info:doi/10.1177/00368504241253709&rft_dat=%3Cproquest_pubme%3E3059256386%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3083714260&rft_id=info:pmid/38778725&rft_sage_id=10.1177_00368504241253709&rfr_iscdi=true |